Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Inhibitor
Kadsuracoccinic acid A is a tetracyclic natural compound targeting HIV-1. It exhibits significant anti-HIV-1 activity in vitro, with an EC50 value of 68.7 μM. This compound is valuable for research in the development of antiviral therapies and understanding HIV-1 inhibition mechanisms. -
HIV Inhibitor
HIV-1 inhibitor-70 is a bifunctional inhibitor targeting both wild-type and K103N mutant reverse transcriptases of HIV-1. This compound effectively disrupts the replication of the virus, making it valuable in HIV research and therapeutic investigations. Its dual inhibitory action provides insights into resistance mechanisms and aids in the development of effective treatments for HIV infections. -
HIV protease inhibitor
SB 204144 is a potent inhibitor of HIV protease, disrupting the proteolytic processing of viral polyproteins and hindering the maturation of infectious HIV particles. This compound is valuable for research on HIV pathogenesis and immune system diseases, enabling studies on antiviral effects and the development of new therapeutic strategies against HIV. Its application in virology underlines its relevance in understanding and combating HIV infection. -
HIV Inhibitor
B07 is a potent HIV inhibitor that targets viral replication mechanisms. In addition to its antiviral properties, B07 also exhibits spermicidal activity with an EC50 of 1.5 mg/mL. This compound has valuable applications in HIV research and the development of contraceptive agents. -
HIV-1 Inhibitor
GS-9822 is a potent HIV-1 inhibitor that specifically targets the LEDGF/p75-integrase interaction, demonstrating robust antiviral activity with an IC50 of 0.07 μM against wild-type HIV-1 viruses. It exhibits high in vitro metabolic stability and favorable oral pharmacokinetic properties, characterized by low systemic clearance across various preclinical animal models, including rats, dogs, and monkeys. GS-9822 is a valuable tool for research applications focused on understanding HIV-1 integration and developing therapeutic strategies against viral infections. -
HIV-1 Inhibitor
Fosamprenavir-d4 is a deuterium-labeled inhibitor targeting HIV-1 protease. As a prodrug of Amprenavir, Fosamprenavir is hydrolyzed by cell phosphatases, converting it into Amprenavir, which subsequently binds to the active site of HIV-1 protease. This binding prevents the processing of essential viral precursors, inhibiting the production of mature and infectious virions. Fosamprenavir-d4 is useful for research focused on HIV-1 infection and therapeutic strategies against the virus. -
HIV Inhibitor
Tsugafolin is a dehydroflavone that acts as an inhibitor of HIV. It exhibits weak anti-HIV activity with an IC50 value of 118 μM while demonstrating low cytotoxicity at concentrations below 150 μM. Isolated from the plant Vitex leptobotrys, Tsugafolin serves as a valuable tool for research applications focused on HIV-1 replication and the development of therapeutic strategies. -
HIV-l Encoded Protease Inhibitor
L-738872 is a potent orally active inhibitor of the HIV-1 encoded protease. It effectively inhibits viral replication by interfering with the processing of viral polyproteins, which is critical for the maturation of infectious HIV particles. This compound is valuable in research focused on understanding HIV protease functionality and developing antiretroviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
Urushiol (15:3) is an inhibitor of HIV-1 reverse transcriptase, demonstrating moderate inhibitory activity with an IC50 value of 55.36 μM. This compound, derived from the leaves of Rhus verniciflua, exhibits significant cytotoxicity against prostate cancer PC-3 cells and normal MRC-5 cells. Urushiol (15:3) is relevant for research into anti-HIV-1 therapies and the study of prostate cancer biology. -
HIV NNRT Inhibitor
BI-2540 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV. This compound exhibits significant antiviral activity by inhibiting the reverse transcription process, thereby preventing viral replication. BI-2540 is utilized in research for the development of therapeutic strategies against HIV and contributes to the understanding of HIV resistance mechanisms. -
HIV-1 RT Inhibitor
L 738372 is a non-competitive reversible inhibitor of HIV-1 reverse transcriptase (RT) with a reported inhibition constant (Ki) of 140 nM against dTTP. This compound demonstrates synergistic inhibition of RT activity when used in combination with nucleoside analogs such as azidothymidine triphosphate, didexoyinosine triphosphate, or didexoycytidine triphosphate. Notably, L 738372 exhibits enhanced inhibitory potency against azidothymidine-resistant RT variants (D67N, K70R, T215Y, K219Q), making it a valuable tool for advancing research in HIV treatment strategies. -
HIV Inhibitor
H-Gly-Pro-Gly-NH2 is a tripeptide that serves as an inhibitor of HIV-1 and HIV-2 replication. Demonstrating EC50 values of 35 µM for HIV-1 IIIB and 30 µM for HIV-2 ROD, H-Gly-Pro-Gly-NH2 reduces viral replication by disrupting capsid formation in vitro. This compound possesses significant antiviral activity, making it a valuable tool for research into HIV and related viral mechanisms. -
HIV-1 Inhibitor
GSK3532795 oxalate is a potent second-generation inhibitor of HIV-1 maturation, acting primarily through the disruption of viral particle assembly. It exhibits notable efficacy with EC50 values of 1.9 nM for HIV-1 wild type, 10.2 nM in human serum, as well as 2.7 nM and 13 nM for the HIV-1 V370A and ΔV370 variants, respectively. This compound is essential for research focused on HIV-1 infection mechanisms and therapeutic strategies. -
HIV-1 Inhibitor
HIV-1 inhibitor-34 is a potent and selective inhibitor of HIV-1, exhibiting an EC50 value of 6.4 nM in HIV-1 assays and a CC50 of 16 μM in MT-4 cells. This compound is valuable for research applications focused on understanding HIV-1 replication and pathogenesis, making it a useful tool for studies related to AIDS therapeutics. -
HIV Inhibitor
SJ-3366 is a potent inhibitor of HIV non-nucleoside reverse transcriptase. This compound demonstrates significant inhibitory activity at sub-nanomolar concentrations, functioning through a typical non-nucleoside mechanism. SJ-3366 is utilized in research applications focused on HIV replication and the development of antiretroviral therapies. -
HIV-I Integrase Inhibitor
Bis-T-23 is a potent inhibitor of HIV-1 integrase, acting through a tyrphostin derivative mechanism. This compound has been shown to promote actin-dependent dynamin oligomerization, highlighting its role in cellular processes related to viral replication. Bis-T-23 is valuable for research focused on HIV and chronic kidney diseases (CKD), providing insights into the intersection of viral infection and renal pathophysiology. -
HIV Inhibitor Prodrug
HIV-IN-13 prodrug is designed as a prodrug of an HIV inhibitor, engaging specifically with viral components upon conversion. In the presence of glutathione (GSH), this compound exhibits significant antiviral activity, demonstrating EC50 values of 10 μM and 8.2 μM against HIV-1 at concentrations of 1 mM and 2 mM GSH, respectively. This prodrug serves as a valuable tool for research focused on HIV infection and therapeutic development. -
HIV-1 Inhibitor
NB-64 is an orally active inhibitor of HIV-1 that targets viral replication. Its significant antiviral activity makes it a valuable tool for research into HIV infections and the development of therapeutic strategies. This compound contributes to a better understanding of HIV pathogenesis and potential treatment options. -
HIV Inhibitor
PNU-142721 is a reverse transcriptase inhibitor that targets HIV by effectively inhibiting various type I variants. This compound serves as a valuable tool in HIV research, particularly in the study of viral replication and resistance mechanisms. Its dual function as a PXR agonist further enhances its relevance in investigating drug metabolism and therapeutic strategies against HIV. -
HIV Integrase Inhibitor
Lepetegravir is a potent HIV integrase inhibitor that exerts its antiviral effects by blocking the integration of viral DNA into the host genome. With an EC50 value of 0.98 nM in MT-4 cells, it demonstrates strong efficacy in suppressing HIV replication. Lepetegravir is applicable in research aimed at understanding HIV pathogenesis and developing antiretroviral therapies. -
HIV-1 Integrase Inhibitor
Integracin B is a potent inhibitor targeting HIV-1 integrase through a dimeric alkyl aromatic structure. It effectively inhibits both the coupled and strand transfer activities of the integrase, making it a valuable tool for studying HIV-1 replication and integration processes. This compound is suitable for research applications focused on antiviral drug development and the mechanistic understanding of integrase-mediated viral entry. -
HIV Inhibitor
HIV-1 Inhibitor-9 is a potent inhibitor targeting HIV-1, effectively inhibiting both wild-type and various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant strains at low nanomolar concentrations. This compound demonstrates significant antiviral activity, making it a valuable tool for research into HIV treatment and drug resistance mechanisms. Its efficacy against resistant strains supports its potential use in therapeutic studies and drug development efforts aimed at combating HIV-1 infection. -
HIV Inhibitor
Tripterifordin is a potent inhibitor of HIV replication, specifically targeting H9 lymphocyte cells. It demonstrates significant anti-HIV activity with an EC50 value of 3100 nM. This compound is valuable for research applications aimed at understanding HIV pathogenesis and developing therapeutic strategies against HIV infection. -
HIV Inhibitor
UK-88947 hydrochloride is a potent HIV protease inhibitor, primarily targeting HIV-1 replication. It effectively disrupts the early stages of the viral life cycle when administered to cells prior to infection. Additionally, UK-88947 hydrochloride inhibits viral protease activity during infection, thereby significantly impacting viral replication. This compound is valuable for research focused on developing therapeutic strategies against HIV. -
HIV Inhibitor
(D-Ala)-Peptide T is an octapeptide that acts as an HIV inhibitor by targeting the HIV-1 envelope glycoprotein gp120. This compound has been shown to release chemokines and protect against neuronal death induced by gp120. It is a valuable reagent for research into infectious diseases and neurological disorders, particularly AIDS-related dementia. -
HIV-1 Inhibitor
HIV-1 Inhibitor-29 is a potent inhibitor targeting the HIV-1 virus, demonstrating an EC50 of 2.18 μM against the HIV-1 IIIB strain. This compound exhibits significant anti-resistance properties against the F227L/V106A mutant strain, with an EC50 of 0.974 μM, while maintaining low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 Inhibitor-29 is a valuable tool for research focused on AIDS and HIV-1 therapeutic development. -
HIV-1 Inhibitor
NNRT-IN-1 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV-1. This compound demonstrates significant anti-resistance efficacy, effectively inhibiting wild-type HIV-1 as well as five mutant strains, with EC50 values in the nanomolar range. Additionally, NNRT-IN-1 exhibits favorable pharmacokinetic properties, making it a valuable tool for research applications in HIV therapeutics. -
HIV Inhibitor
(+)-Carbovir is a nucleoside analog specifically designed to inhibit human immunodeficiency virus type 1 (HIV-1). Its enhanced chemical and metabolic stability contributes to its antiviral efficacy. This compound serves as a valuable tool in AIDS research, facilitating studies aimed at understanding and combating HIV infection. -
HIV-1 RT Inhibitor
Tivirapine is a non-nucleoside inhibitor targeting HIV-1 reverse transcriptase (RT), demonstrating potent antiviral activity with an EC50 value of 4 nM. This compound effectively inhibits the Y181C mutant of HIV-1 RT, offering a valuable tool for studying drug resistance mechanisms and evaluating therapeutic strategies against HIV-1 infection. Its application is relevant in both basic research and development of novel antiviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-64 (Compound 7c) is a potent antagonist targeting HIV-1, demonstrating effective inhibition of both wild-type and resistant mutants, specifically E138K/Q148K and G140S/Q148R, with EC50 values of 62.5 nM and 11.3 nM, respectively. This compound exhibits significant antiviral activity, making it a valuable tool for AIDS research and studies focused on HIV-1 resistance mechanisms. -
HIV-1 Inhibitor
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1 with an EC50 of 1.9 nM, demonstrating potent antiviral activity. This compound exhibits minimal interaction with cytochrome P450 enzymes, with IC50 values of 5.16 μM for CYP2C9 and 4.51 μM for CYP2C19, indicating its favorable profile for therapeutic applications. Notably, HIV-1 inhibitor-40 shows no significant acute toxicity in vivo, making it a promising candidate for further research in HIV treatment. -
HIV Inhibitor
Influenza antiviral conjugate-1 (INT-2) is an HIV inhibitor that exhibits potent cell fusion inhibition. This compound serves as a click chemistry reagent, featuring an alkyne group capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application in biological research allows for the development of innovative therapeutic strategies and the study of viral entry mechanisms. -
HIV REV/RRE Interaction Inhibitor
Niruriside is an inhibitor of the HIV REV/RRE complex, specifically targeting the interaction between the HIV REV protein and RRE RNA with an IC50 of 3.3 μM. This compound exhibits selectivity, showing no significant effects on the unrelated R17 capsid protein/operator RNA binding system. While Niruriside does not protect CEM-SS cells from acute HIV-1 infection, it serves as a valuable tool for investigating the mechanisms of HIV infection and the role of the REV/RRE interaction in viral replication and pathogenesis. -
HIV-1 Inhibitor
L 696229 is a selective inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), demonstrating significant antiviral activity. This compound is primarily utilized in the study of HIV replication and the development of antiretroviral therapies, offering insights into viral resistance mechanisms and potential therapeutic interventions. Its specificity for RT makes it a valuable tool in HIV research and drug discovery. -
HIV-1 Inhibitor
Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and functions as a prodrug for Amprenavir. Upon administration, it is hydrolyzed by cell phosphatases in the intestinal epithelium to release Amprenavir, which inhibits HIV-1 protease by binding to its active site. This binding prevents the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the maturation of infectious virus particles. Fosamprenavir sodium is valuable for research on human immunodeficiency virus (HIV-1) infection. -
HIV-1 Inhibitor
HIV-1 inhibitor-35 is a potent inhibitor of HIV-1, exhibiting EC50 values of 80 nM and 70 nM against LTR and CMV in HEK293 cells, respectively. This compound also demonstrates cytotoxic activity against HepG2 liver cancer cells, with a CC50 of 40 nM. HIV-1 inhibitor-35 is suitable for research applications in HIV-1 latency reversal and antiviral therapeutic investigations. -
HIV Inhibitor
GB-1a is a biflavanone that functions as an inhibitor of HIV-1 reverse transcriptase, demonstrating an IC50 value of 236 μM and an EC50 of 38.0 μM for HIV-1 replication. This compound effectively prevents the conversion of HIV-1 genomic RNA into DNA, making it a valuable tool for research on AIDS and HIV-1 infection. Additionally, GB-1a can be naturally sourced from the heartwood of Garcinia multiflora Champ, further emphasizing its potential for biological study. -
HIV-1 Inhibitor
AIC-292 is a selective inhibitor of HIV-1 nonnucleoside reverse transcriptase, demonstrating potent antiviral activity against wild-type HIV-1 laboratory strains at low nanomolar concentrations. This compound exhibits significant in vivo efficacy in mouse xenograft models, making it a valuable tool for research into HIV-1 infection and antiretroviral therapies. AIC-292 may aid in the development of innovative therapeutic strategies targeting HIV-1. -
HIV Inhibitor
HIV-1 inhibitor-38 is a potent HIV-1 inhibitor that exhibits effective antiviral activity against the virus responsible for HIV/AIDS. Its unique mechanism of action positions it as a potential candidate for further development as a latency-reversing agent, making it a valuable tool in HIV research and therapeutic investigation. This compound is particularly relevant for studies focused on viral eradication and understanding HIV latency. -
HIV-1 Inhibitor
HIV-IN-5 is a potent HIV-1 inhibitor that targets the non-nucleoside reverse transcriptase inhibitor binding pocket (NNIBP). It exhibits an IC50 value of 0.16 μM for inhibiting viral replication and demonstrates interference with HIV DNA-dependent DNA polymerization activity with an IC50 of 2.18 μM. This compound is valuable for research focused on HIV-1 antiviral mechanisms and the development of therapeutic agents targeting HIV replication. -
HIV-1 Inhibitor
HIV-1 Inhibitor-13 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. With an IC50 of 0.14 μM against HIV-1 reverse transcriptase, it demonstrates significant antiviral activity. This compound also exhibits effectiveness against various HIV-1 resistant strains, with EC50 values ranging from 2.85 to 18.0 nM, making it a valuable tool for HIV research and therapeutics development. -
HIV-1 Inhibitor
HIV-1 Inhibitor-15 is a potent and broad-spectrum inhibitor of HIV-1, targeting various strains including HIV-1 WT, L100I, K103N, Y181C, and E138K. It demonstrates impressive inhibitory activity with EC50 values of 1.7 nM, 4 nM, 2 nM, 6 nM, and 9 nM, respectively. This compound features excellent solubility and safety profiles, along with favorable oral bioavailability, making it valuable for research applications in the study of HIV-1 treatment mechanisms and resistance. -
HIV-1 Inhibitor
U-104489 is a potent inhibitor of HIV-1, targeting the reverse transcriptase (RT) enzyme. It demonstrates Ki values of 0.13 μM against the wild-type p66/p51 variant (G190), and 0.12 μM against the G190A variant, while exhibiting significantly reduced activity (Ki > 100 μM) against the G190E variant. This compound is valuable for research applications aimed at understanding HIV-1 resistance mechanisms and developing effective antiretroviral therapies. -
HIV-Nef Protein Inhibitor
ZINC04177596 is a potent inhibitor of the HIV-negative factor (HIV-Nef) protein. The Nef protein plays a critical role in HIV replication and contributes to the pathogenesis of AIDS. This compound is valuable for research into therapeutic strategies targeting HIV infection and understanding the molecular mechanisms underlying viral replication. -
HIV-1 Inhibitor
Patentiflorin A is a potent HIV-1 inhibitor that targets viral replication. It has demonstrated broad-spectrum activity against various strains of the virus, including those resistant to conventional treatments. This compound is valuable for research focused on understanding HIV-1 pathogenesis and developing new therapeutic strategies to combat drug-resistant strains. -
HIV-1 Inhibitor
Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl is an HIV-1 inhibitor that primarily targets the gp120 protein. By interfering with the interaction between gp120 and the CD4 receptor, this compound preserves CD4-dependent T cell function. Its inhibitory activity makes it a valuable tool for research focused on HIV-1 infection and immune response modulation. -
HIV Inhibitor
HIV-1 inhibitor-47 targets HIV-1 by inhibiting the vif-dependent degradation of human APOBEC3G, exhibiting an IC50 value of 14.33 μM. This compound is valuable in studying HIV pathogenesis and the role of host immunity involved in viral replication. Additionally, HIV-1 inhibitor-47 is implicated in the synthesis of derivatives of 1-(2-pyrimidinyl)piperazine, which may possess antianxiety, antidepressant, and antipsychotic properties, expanding its potential applications in neuropharmacology. -
HIV-1 Inhibitor
HIV-1 inhibitor-46 is a potent non-nucleoside reverse transcriptase inhibitor targeting HIV-1. With an EC50 value of 1.425 μM, it effectively hinders viral replication. This compound is valuable for research into HIV/AIDS and the development of therapeutic strategies to combat the virus. -
HIV-1 Inhibitor
HIV-1 inhibitor-39 (compound 3c) is a potent inhibitor of HIV-1 reverse transcriptase (RT), exhibiting an IC50 of 15.75 µM. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for research in HIV therapy. Additionally, while it shows cytotoxic effects in MT-4 cells with a CC50 of 112.9 µM, its efficacy in inhibiting viral replication positions it as a promising candidate for further investigation in HIV-related studies. -
HIV-1 Inhibitor
HIV-1 inhibitor-30 is a potent inhibitor of HIV-1 reverse transcriptase, demonstrating an EC50 of 40 nM and an IC50 of 80 nM. This compound exhibits significant antiviral activity against various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains, with IC50 values ranging from 0.04 to 1.42 μM. HIV-1 inhibitor-30 is a valuable tool for studying HIV/AIDS pathogenesis and developing therapeutic strategies against resistant viral strains.
